Harrow (NASDAQ:HROW) Now Covered by Analysts at William Blair

William Blair assumed coverage on shares of Harrow (NASDAQ:HROW - Free Report) in a report issued on Tuesday morning, MarketBeat reports. The brokerage issued an outperform rating on the stock.

Several other brokerages have also commented on HROW. HC Wainwright lifted their price objective on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, May 12th. B. Riley reduced their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Harrow currently has a consensus rating of "Buy" and an average price target of $61.25.

Harrow Stock Performance

NASDAQ:HROW traded up $1.02 during mid-day trading on Tuesday, reaching $31.17. The company's stock had a trading volume of 532,210 shares, compared to its average volume of 500,087. The company has a current ratio of 1.55, a quick ratio of 1.44 and a debt-to-equity ratio of 3.23. The stock has a market cap of $1.14 billion, a P/E ratio of -33.16 and a beta of 0.40. The firm's fifty day moving average price is $25.53 and its two-hundred day moving average price is $29.82. Harrow has a 12-month low of $16.87 and a 12-month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $47.83 million for the quarter, compared to analysts' expectations of $57.00 million. On average, equities analysts forecast that Harrow will post -0.53 EPS for the current fiscal year.

Institutional Investors Weigh In On Harrow

A number of institutional investors have recently bought and sold shares of HROW. Rhumbline Advisers boosted its stake in shares of Harrow by 7.2% in the first quarter. Rhumbline Advisers now owns 42,975 shares of the company's stock worth $1,143,000 after acquiring an additional 2,879 shares during the period. Strs Ohio bought a new position in Harrow in the 1st quarter worth approximately $149,000. Dynamic Technology Lab Private Ltd grew its holdings in Harrow by 34.7% during the 1st quarter. Dynamic Technology Lab Private Ltd now owns 16,908 shares of the company's stock valued at $450,000 after buying an additional 4,358 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Harrow by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company's stock valued at $483,000 after buying an additional 790 shares during the last quarter. Finally, Braidwell LP lifted its holdings in shares of Harrow by 5.5% in the first quarter. Braidwell LP now owns 956,839 shares of the company's stock worth $25,452,000 after buying an additional 49,800 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.